Pancreatic Cancer - Pipeline Review, H2 2017

Date: December 29, 2017
Pages: 2270
Price:
US$ 2,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PE633B95348EN
Leaflet:

Download PDF Leaflet

Pancreatic Cancer - Pipeline Review, H2 2017
Pancreatic Cancer - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H2 2017, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape.

Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood clots. Predisposing factors include age, gender, smoking, diabetes and family history. Treatment includes surgery, chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pancreatic Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatic Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 16, 132, 124, 2, 8, 280, 39 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 18, 9, 1, 50 and 8 molecules, respectively.

Pancreatic Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pancreatic Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pancreatic Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Cancer (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pancreatic Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pancreatic Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Pancreatic Cancer - Overview
Pancreatic Cancer - Therapeutics Development
Pancreatic Cancer - Therapeutics Assessment
Pancreatic Cancer - Companies Involved in Therapeutics Development
Pancreatic Cancer - Drug Profiles
Pancreatic Cancer - Dormant Projects 2167
Pancreatic Cancer - Discontinued Products 2188
Pancreatic Cancer - Product Development Milestones 2193
Appendix 2203

LIST OF TABLES

Number of Products under Development for Pancreatic Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pancreatic Cancer - Pipeline by 3-V Biosciences Inc, H2 2017
Pancreatic Cancer - Pipeline by 4P-Pharma SAS, H2 2017
Pancreatic Cancer - Pipeline by 4SC AG, H2 2017
Pancreatic Cancer - Pipeline by AB Science SA, H2 2017
Pancreatic Cancer - Pipeline by AbbVie Inc, H2 2017
Pancreatic Cancer - Pipeline by AbGenomics International Inc, H2 2017
Pancreatic Cancer - Pipeline by Ability Pharmaceuticals SL, H2 2017
Pancreatic Cancer - Pipeline by Aclaris Therapeutics Inc, H2 2017
Pancreatic Cancer - Pipeline by Actuate Therapeutics Inc, H2 2017
Pancreatic Cancer - Pipeline by Adamed Sp z oo, H2 2017
Pancreatic Cancer - Pipeline by Aduro BioTech Inc, H2 2017
Pancreatic Cancer - Pipeline by Advanced Cancer Therapeutics LLC, H2 2017
Pancreatic Cancer - Pipeline by Advantagene Inc, H2 2017
Pancreatic Cancer - Pipeline by AGV Discovery SAS, H2 2017
Pancreatic Cancer - Pipeline by AIMM Therapeutics BV, H2 2017
Pancreatic Cancer - Pipeline by Alissa Pharma, H2 2017
Pancreatic Cancer - Pipeline by Allinky Biopharma, H2 2017
Pancreatic Cancer - Pipeline by Almac Discovery Ltd, H2 2017
Pancreatic Cancer - Pipeline by Altor BioScience Corp, H2 2017
Pancreatic Cancer - Pipeline by Ambrx Inc, H2 2017
Pancreatic Cancer - Pipeline by amcure GmbH, H2 2017
Pancreatic Cancer - Pipeline by American Gene Technologies International Inc, H2 2017
Pancreatic Cancer - Pipeline by Amgen Inc, H2 2017
Pancreatic Cancer - Pipeline by Anavex Life Sciences Corp, H2 2017
Pancreatic Cancer - Pipeline by Andarix Pharmaceuticals Inc, H2 2017
Pancreatic Cancer - Pipeline by ANP Technologies Inc, H2 2017
Pancreatic Cancer - Pipeline by AntiCancer Inc, H2 2017
Pancreatic Cancer - Pipeline by APEIRON Biologics AG, H2 2017
Pancreatic Cancer - Pipeline by Apexigen Inc, H2 2017
Pancreatic Cancer - Pipeline by Aphios Corp, H2 2017
Pancreatic Cancer - Pipeline by APIM Therapeutics AS, H2 2017
Pancreatic Cancer - Pipeline by Aposense Ltd, H2 2017
Pancreatic Cancer - Pipeline by ARMO Biosciences Inc, H2 2017
Pancreatic Cancer - Pipeline by ArQule Inc, H2 2017
Pancreatic Cancer - Pipeline by Array BioPharma Inc, H2 2017
Pancreatic Cancer - Pipeline by Astellas Pharma Inc, H2 2017
Pancreatic Cancer - Pipeline by AstraZeneca Plc, H2 2017
Pancreatic Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2017
Pancreatic Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H2 2017
Pancreatic Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2017
Pancreatic Cancer - Pipeline by Bavarian Nordic A/S, H2 2017
Pancreatic Cancer - Pipeline by Bayer AG, H2 2017
Pancreatic Cancer - Pipeline by BeiGene Ltd, H2 2017
Pancreatic Cancer - Pipeline by Bellicum Pharmaceuticals Inc, H2 2017
Pancreatic Cancer - Pipeline by Berg LLC, H2 2017
Pancreatic Cancer - Pipeline by BerGenBio ASA, H2 2017
Pancreatic Cancer - Pipeline by Bexion Pharmaceuticals LLC, H2 2017
Pancreatic Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017
Pancreatic Cancer - Pipeline by Bio-Path Holdings Inc, H2 2017
Pancreatic Cancer - Pipeline by BioLineRx Ltd, H2 2017
Pancreatic Cancer - Pipeline by BioMoti Ltd, H2 2017
Pancreatic Cancer - Pipeline by Biomunex Pharmaceuticals, H2 2017
Pancreatic Cancer - Pipeline by Bionomics Ltd, H2 2017
Pancreatic Cancer - Pipeline by BioNTech AG, H2 2017
Pancreatic Cancer - Pipeline by Biouniversa srl, H2 2017
Pancreatic Cancer - Pipeline by BLR Bio LLC, H2 2017
Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Pancreatic Cancer - Pipeline by Boston Biomedical Inc, H2 2017
Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2017
Pancreatic Cancer - Pipeline by Calithera Biosciences Inc, H2 2017
Pancreatic Cancer - Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2017
Pancreatic Cancer - Pipeline by Cantargia AB, H2 2017
Pancreatic Cancer - Pipeline by Cantex Pharmaceuticals Inc, H2 2017
Pancreatic Cancer - Pipeline by CARsgen Therapeutics Ltd, H2 2017

LIST OF FIGURES

Number of Products under Development for Pancreatic Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

3-V Biosciences Inc
4P-Pharma SAS
4SC AG
AB Science SA
AbbVie Inc
AbGenomics International Inc
Ability Pharmaceuticals SL
Aclaris Therapeutics Inc
Actuate Therapeutics Inc
Adamed Sp z oo
Aduro BioTech Inc
Advanced Cancer Therapeutics LLC
Advantagene Inc
AGV Discovery SAS
AIMM Therapeutics BV
Alissa Pharma
Allinky Biopharma
Almac Discovery Ltd
Altor BioScience Corp
Ambrx Inc
amcure GmbH
American Gene Technologies International Inc
Amgen Inc
Anavex Life Sciences Corp
Andarix Pharmaceuticals Inc
ANP Technologies Inc
AntiCancer Inc
APEIRON Biologics AG
Apexigen Inc
Aphios Corp
APIM Therapeutics AS
Aposense Ltd
ARMO Biosciences Inc
ArQule Inc
Array BioPharma Inc
Astellas Pharma Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
AVEO Pharmaceuticals Inc
Axcentua Pharmaceuticals AB
Basilea Pharmaceutica Ltd
Bavarian Nordic A/S
Bayer AG
BeiGene Ltd
Bellicum Pharmaceuticals Inc
Berg LLC
BerGenBio ASA
Bexion Pharmaceuticals LLC
BeyondSpring Pharmaceuticals Inc
Bio-Path Holdings Inc
BioLineRx Ltd
BioMoti Ltd
Biomunex Pharmaceuticals
Bionomics Ltd
BioNTech AG
Biouniversa srl
BLR Bio LLC
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Cancer Prevention Pharmaceuticals Inc
Cantargia AB
Cantex Pharmaceuticals Inc
CARsgen Therapeutics Ltd
Cascadian Therapeutics Inc
CBT Pharmaceuticals Inc
CCRP Therapeutics GmbH
Celgene Corp
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Celleron Therapeutics Ltd
Cellular Biomedicine Group Inc
Celprogen Inc
Celyad SA
Centrose LLC
Ceronco Biosciences
Chem-Master International Inc
ChemoCentryx Inc
Chugai Pharmaceutical Co Ltd
Clovis Oncology Inc
COARE Biotechnology Inc
Codiak BioSciences Inc
Concordia International Corp
Critical Outcome Technologies Inc
CrystalGenomics Inc
CTI BioPharma Corp
Cyclacel Pharmaceuticals Inc
CytImmune Sciences Inc
Cytori Therapeutics Inc
CyTuVax BV
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
DEKK-TEC Inc
Denceptor Therapeutics Ltd
Diffusion Pharmaceuticals Inc
Eisai Co Ltd
Eleison Pharmaceuticals LLC
Eli Lilly and Co
Endor Nanotechnologies SL
Ensemble Therapeutics Corp
Ensol Biosciences Inc
Erytech Pharma SA
Esperance Pharmaceuticals Inc
Etubics Corp
Exelixis Inc
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Felicitex Therapeutics Inc
FibroGen Inc
Formosa Laboratories Inc
Forty Seven Inc
Fountain Biopharma Inc
Fujifilm Holdings Corporation
Fusion Antibodies Ltd
Galena Biopharma Inc
Galera Therapeutics Inc
GamaMabs Pharma SA
Geistlich Pharma AG
Genelux Corp
Genentech Inc
Genisphere LLC
Genoscience Pharma
Gilead Sciences Inc
GlaxoSmithKline Plc
GlycoMimetics Inc
Glycotope GmbH
Golden Biotechnology Corp
GW Pharmaceuticals Plc
Halozyme Therapeutics Inc
Heidelberg Pharma AG
Helix BioPharma Corp
Hemispherx Biopharma Inc
Horizon Pharma Plc
iCeutica Inc
Idera Pharmaceuticals Inc
Igenica Biotherapeutics Inc
Ignyta Inc
Immodulon Therapeutics Ltd
Immune System Key Ltd
Immunitor Inc
Immunomedics Inc
Immunotope Inc
Immunovo BV
Immupharma Plc
Incyte Corp
Inflection Biosciences Ltd
Innopharmax Inc
Innovation Pharmaceuticals Inc
Inovio Pharmaceuticals Inc
InteRNA Technologies BV
Intezyne Technologies Inc
Inventiva
InvivoGen Therapeutics
Io Therapeutics Inc
Iovance Biotherapeutics Inc
Ipsen SA
ISU ABXIS Co Ltd
Jasco Pharmaceuticals LLC
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Juno Therapeutics Inc
Kalyra Pharmaceuticals Inc
Kancera AB
Karcinolys SAS
Karyopharm Therapeutics Inc
Kazia Therapeutics Ltd
Keystone Nano Inc
Komipharm International Co Ltd
Kringle Pharma Inc
Kura Oncology Inc
Kyowa Hakko Kirin Co Ltd
Lead Discovery Center GmbH
Lidds AB
LIfT BioSciences Ltd
Lixte Biotechnology Holdings Inc
Loxo Oncology Inc
Lymphocyte Activation Technologies SA
MabVax Therapeutics Holdings Inc
MacroGenics Inc
Madrigal Pharmaceuticals Inc.
MaxiVAX SA
Meabco AS
Mebiopharm Co Ltd
MediaPharma SRL
Medicenna Therapeutics Corp
MedImmune LLC
Medivir AB
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Merus NV
Millennium Pharmaceuticals Inc
Moderna Therapeutics Inc
Molecular Partners AG
Molecular Templates Inc
Moleculin Biotech Inc
MolMed SpA
Monopar Therapeutics LLC
Morphotek Inc
NanoCarrier Co Ltd
NanoVector Inc
NantKwest Inc
Nascent Biotech Inc
Natco Pharma Ltd
NatureWise Biotech & Medicals Corp
NBE-Therapeutics AG
Nerviano Medical Sciences Srl
NewLink Genetics Corp
NormOxys Inc
Novartis AG
Noxxon Pharma AG
NuCana Plc
OBI Pharma Inc
Omeros Corp
Oncodesign SA
Oncolytics Biotech Inc
Oncomatryx Biopharma SL
OncoMed Pharmaceuticals Inc
OncoTherapy Science Inc
Oncovir Inc
Ono Pharmaceutical Co Ltd
Opsona Therapeutics Ltd
Optimum Therapeutics LLC
Orega Biotech SAS
Oribase Pharma
Oryx GmbH & Co KG
OSE Immunotherapeutics
Oxford BioTherapeutics Ltd
Patrys Ltd
Pfizer Inc
Pharma Two B Ltd
PharmAbcine Inc
PharmaCyte Biotech Inc
Pharmedartis GmbH
Phoenix Biotechnology Inc
Plexxikon Inc
Polaris Pharmaceuticals Inc
Precision Biologics Inc
Prescient Therapeutics Ltd
Propanc Biopharma Inc
Provectus Biopharmaceuticals Inc
Puretech Health plc
Quest PharmaTech Inc
Quimatryx SL
Rafael Pharmaceuticals Inc
RedHill Biopharma Ltd
Redx Pharma Plc
Rexahn Pharmaceuticals Inc
Rhizen Pharmaceuticals SA
Sagetis Biotech SL
Samumed LLC
Samyang Holdings Corp
Sanofi
Sareum Holdings Plc
SATT North SAS
Scancell Holdings Plc
Selecta Biosciences Inc
Siamab Therapeutics Inc
Sierra Oncology Inc
SignPath Pharma Inc
SilaGene Inc
Silenseed Ltd
Sillajen Biotherapeutics
Sino Biopharmaceutical Ltd
Soricimed Biopharma Inc
Sorrento Therapeutics Inc
Spring Bank Pharmaceuticals Inc
Stelic Institute & Co Inc
Strongbridge Biopharma plc
Sumitomo Dainippon Pharma Co Ltd
Sun BioPharma Inc
Sun Pharma Advanced Research Company Ltd
Sunshine Biopharma Inc
Swedish Orphan Biovitrum AB
Symphogen A/S
SynCore Biotechnology Co Ltd
Syndax Pharmaceuticals Inc
Synergys Biotherapeutics Inc
Synovo GmbH
SyntheX Inc
Taiho Pharmaceutical Co Ltd
Taiwan Liposome Company Ltd
Takara Bio Inc
Takeda Pharmaceutical Co Ltd
Takis Srl
Targovax ASA
Tarveda Therapeutics Inc
tella Inc
Tiltan Pharma Ltd
Tiziana Life Sciences Plc
Tocagen Inc
Transcriptogen Ltd
Transgene SA
TVAX Biomedical Inc
Tyg Oncology Ltd
Tyme Technologies Inc
Tyrogenex Inc
UbiVac LLC
ValiRx Plc
VasGene Therapeutics Inc
Vault Pharma Inc
Vaxeal Holding SA
Vaximm AG
Vaxon Biotech
VCN Biosciences SL
Vect-Horus SAS
Verastem Inc
VG Life Sciences Inc
Vicus Therapeutics LLC
ViiV Healthcare UK Ltd
Viralytics Ltd
Virobay Inc
ViroStatics srl
Zeria Pharmaceutical Co Ltd
Skip to top


Ask Your Question

Pancreatic Cancer - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: